John Quisel, Disc Medicine CEO
With promising PhII blood disorder data in hand, Disc Medicine seeks $100M in public offering
Disc Medicine is looking for even more capital to fund its candidates for blood disorders on the heels of a $62.5 million direct offering and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
